IUS Combined With VAT Predicts Anti-TNF-a Efficacy in Patients With IBD: a Prospective Study

Recruiting

• Conditions: Inflammatory Bowel Diseases; Intestinal Ultrasound; Visceral Adipose Tissue; TNF-a; Predictors

• Registration Number: NCT06165029
• Lead Sponsor: The Third Xiangya Hospital of Central South University

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2023-11-20
• Last Update Posted: 2 September 2024

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Inclusion Criteria:<br><br> - Age = 18 years and = 80 years;<br><br> - Patients with newly diagnosed or relapsed active IBD;<br><br> - Anti-TNF-a monotherapy is proposed to be applied within 1 month after baseline<br> endoscopy;<br><br> - No history of abdominal surgery;<br><br> - Clearly understand, voluntarily participate in the study, and sign an informed<br> consent form.<br><br>Exclusion Criteria:<br><br> - Contraindications to anti-TNF-a therapy: allergy, active tuberculosis or other<br> active infections, moderate-to-severe heart failure (NYHA grade III/IV),<br> demyelinating lesions of the nervous system, live vaccination within the last 3<br> months, pregnancy and lactation;<br><br> - Patients with a history of extensive colectomy or recent proposed colectomy, history<br> of colonic mucosal dysplasia;<br><br> - Hypersensitivity to the components of SonoVue contrast media.

Exclusion Criteria

Not provided

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Bowel wall thickness (BWT);visceral adipose tissue (VAT)